Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.45 |
| ▸ | RAB9A | P51151 | 10/20 | 0.45 |
| ▸ | MAPT | P10636 | 9/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.45 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069436 | 0.87 | MAPT (0.54) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL770131 | 0.85 | RAB9A (0.58) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL15799974 | 0.78 | GAA (0.45) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL769663 | 0.77 | RAB9A (0.58) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL15201646 | 0.74 | MAPT (0.56) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL2069427 | 0.72 | MAPT (0.47) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL770102 | 0.71 | MAPT (0.70) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL15213067 | 0.70 | MAPT (0.47) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL2069816 | 0.70 | MAPT (0.43) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL15213085 | 0.69 | MEN1 (0.41) | NPC1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754082-B2 | Antiviral drugs for treatment of Arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-20140128426-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2014-05-08 | — | — | US | claimed |
| EP-2182805-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC (US) | 2013-06-26 | — | — | EP | claimed |
| US-8461177-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. | 2011-03-17 | — | — | US | claimed |
| EP-2182805-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Siga Technologies, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009029622-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-03-05 | — | — | WO | claimed |
| US-9096597-B2 | Antiviral drugs for treatment of Arenavirus infection | Kineta Four, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096597-B2 | Antiviral drugs for treatment of Arenavirus infection | Kineta Four, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096597-B2 | Antiviral drugs for treatment of Arenavirus infection | Kineta Four, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140243367-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243367-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243367-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8461177-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461177-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. | 2011-03-17 | — | — | US | disclosed |
| EP-2182805-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Siga Technologies, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009029622-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | EIF2AK2, ZC3HAV1, SARS1 | NPC1 284/4885RAB9A 2793/4885MAPT 4118/4885 |
| US-20140128426-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | EIF2AK2, ZC3HAV1, SARS1 | NPC1 284/4885RAB9A 2793/4885MAPT 4118/4885 |
| US-20140243367-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | NPC1 284/4885RAB9A 2793/4885MAPT 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.